Back to Journals » OncoTargets and Therapy » Volume 9

Original Research

Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial

       
Total article views   HTML views PDF downloads Totals
12,036 Dovepress* 9,197+ 1,303 10,500
PubMed Central* 2,839 793 3,632
Totals 12,036 2,096 14,132
*Since 16 November 2016
Total mentioned Facebook Delicious Reddit Twitter Others
3 0 0 0 1 2

View citations on PubMed and Google Scholar